Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.

Guolo F, Minetto P, Clavio M, Miglino M, Colombo N, Cagnetta A, Cea M, Marcolin R, Todiere A, Ballerini F, Gobbi M, Lemoli RM.

Br J Haematol. 2019 Jul 26. doi: 10.1111/bjh.16116. [Epub ahead of print] No abstract available.

PMID:
31348524
2.

Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies.

Furfaro E, Giacobbe DR, Del Bono V, Signori A, Guolo F, Minetto P, Clavio M, Ballerini F, Gobbi M, Viscoli C, Mikulska M.

Mycoses. 2018 Sep;61(9):650-655. doi: 10.1111/myc.12787. Epub 2018 Jun 13.

PMID:
29693758
3.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL.

Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

PMID:
29674440
4.

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.

Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Fugazza G, Matarese S, Guardo D, Ballerini F, Di Grazia C, Raiola AM, Cagnetta A, Cea M, Miglino M, Lemoli RM, Gobbi M.

Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23. No abstract available.

PMID:
29359798
5.

A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.

Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Giannoni L, Ballerini F, Lemoli RM, Gobbi M, Miglino M.

Am J Hematol. 2018 Feb;93(2):E33-E35. doi: 10.1002/ajh.24956. Epub 2017 Nov 17. No abstract available.

6.

Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.

Guolo F, Ferrari M, Minetto P, Matteo C, Clavio M, Coviello E, Ballerini F, Miglino M, Gobbi M, D'Incalci M, Lemoli RM, Zucchetti M.

Hematol Oncol. 2018 Apr;36(2):498-499. doi: 10.1002/hon.2484. Epub 2017 Oct 20. No abstract available.

PMID:
29052244
7.

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.

Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, Di Grazia C, Colombo N, Pozzi S, Ibatici A, Bagnasco S, Guardo D, Kunkl A, Ballerini F, Ghiggi C, Lemoli RM, Gobbi M, Bacigalupo A.

Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11. No abstract available.

8.

Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.

Grignolo S, Tatarelli P, Guolo F, Minetto P, Rivoli G, Guardo D, Del Bono V, Varaldo R, Gualandi F, Ballerini F, Raiola A, Gobbi M, Viscoli C, Mikulska M.

Infection. 2017 Aug;45(4):505-511. doi: 10.1007/s15010-017-1010-7. Epub 2017 Mar 28.

PMID:
28353153
9.

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.

Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M.

Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15.

10.

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.

Cagnetta A, Lovera D, Grasso R, Colombo N, Canepa L, Ballerini F, Calvio M, Miglino M, Gobbi M, Lemoli R, Cea M.

Biomed Res Int. 2015;2015:943096. doi: 10.1155/2015/943096. Epub 2015 Oct 22. Review.

11.

Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.

Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano L, Zannetti BA, Rizzi S, Volpe S, Zamagni E, Liberati AM, Mancuso K, Boccadoro M, Davies FE, Morgan GJ, Palumbo A, Cavo M.

Bone Marrow Transplant. 2015 May;50(5):673-8. doi: 10.1038/bmt.2014.322. Epub 2015 Feb 2.

PMID:
25642764
12.

IL-1β-releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors.

Vitale C, Ambrosini P, Montaldo E, Ballerini F, Moretta L, Mingari MC.

Haematologica. 2015 Feb;100(2):e42-5. doi: 10.3324/haematol.2014.110494. Epub 2014 Oct 24. No abstract available.

13.

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.

Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4.

PMID:
24989345
14.

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.

Marani C, Clavio M, Grasso R, Colombo N, Guolo F, Kunkl A, Ballerini F, Giannoni L, Ghiggi C, Fugazza G, Ravetti JL, Gobbi M, Miglino M.

Leuk Res. 2013 Dec;37(12):1606-11. doi: 10.1016/j.leukres.2013.07.005. Epub 2013 Jul 23.

PMID:
23891447
15.

De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".

Clavio M, Cruciani F, Minetto P, Guolo F, Ballerini F, Marani C, De Astis E, Aquino S, Bergamaschi M, Mitscheunig L, Grasso R, Colombo N, Ghiggi C, Lovera D, Pastori G, Avenoso D, Miglino M, Gobbi M.

Ann Hematol. 2013 Oct;92(10):1309-18. doi: 10.1007/s00277-013-1780-7. Epub 2013 May 18.

PMID:
23686116
16.

Hallux valgus in males--part 2: radiographic assessment of surgical treatment.

Nery C, Coughlin MJ, Baumfeld D, Ballerini FJ, Kobata S.

Foot Ankle Int. 2013 May;34(5):636-44. doi: 10.1177/1071100713475351. Epub 2013 Jan 30.

PMID:
23637233
17.

Hallux valgus in males--part 1: demographics, etiology, and comparative radiology.

Nery C, Coughlin MJ, Baumfeld D, Ballerini FJ, Kobata S.

Foot Ankle Int. 2013 May;34(5):629-35. doi: 10.1177/1071100713475350. Epub 2013 Feb 5.

PMID:
23386751
18.

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.

Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M.

Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036. Epub 2012 Oct 29.

PMID:
23108928
19.

Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A.

Biol Blood Marrow Transplant. 2013 Jan;19(1):117-22. doi: 10.1016/j.bbmt.2012.08.014. Epub 2012 Aug 29.

20.

Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression.

Miglino M, Colombo N, Grasso R, Marani C, Clavio M, Pica GM, Ballerini F, Ghiggi C, Minetto P, Guolo F, Carella AM, Gobbi M.

Leuk Lymphoma. 2012 Nov;53(11):2214-7. doi: 10.3109/10428194.2012.681658. Epub 2012 May 21.

PMID:
22475129
21.

WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.

Miglino M, Colombo N, Pica G, Grasso R, Clavio M, Bergamaschi M, Ballerini F, Ghiso A, Ghiggi C, Mitscheunig L, Beltrami G, Cagnetta A, Vignolo L, Lucchetti MV, Aquino S, Pierri I, Sessarego M, Carella AM, Gobbi M.

Leuk Lymphoma. 2011 Oct;52(10):1961-9. doi: 10.3109/10428194.2011.585673.

PMID:
21942328
22.

Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.

Bassetti M, Aversa F, Ballerini F, Benedetti F, Busca A, Cascavilla N, Concia E, Tendas A, Di Raimondo F, Mazza P, Nosari AM, Rossi G.

Clin Drug Investig. 2011 Nov 1;31(11):745-58. doi: 10.2165/11593760-000000000-00000. Review.

PMID:
21888451
23.

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.

Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, Califano C, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A, Brioli A, Tosi P, Baccarani M.

J Clin Oncol. 2009 Oct 20;27(30):5001-7. doi: 10.1200/JCO.2009.22.7389. Epub 2009 Aug 31.

PMID:
19720903
24.

The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.

Olcese F, Clavio M, Rossi E, Spriano M, Ballerini F, Canepa L, Pierri I, Aquino S, Varaldo R, Manna A, Secondo V, Racchi O, Balleari E, Orcioni GF, Carella AM, Ghio R, Gobbi M.

Ann Hematol. 2009 Sep;88(9):855-61. doi: 10.1007/s00277-009-0699-5. Epub 2009 Feb 3.

PMID:
19189105
25.

Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.

Miglino M, Grasso R, Varaldo R, Fugazza G, Colombo N, Clavio M, Canepa L, Garuti A, Ibatici A, Pierri I, Ballerini F, Sessarego M, Gobbi M.

Leuk Lymphoma. 2006 Jul;47(7):1348-51.

PMID:
16923567
26.

Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.

Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.

Oncol Rep. 2005 Oct;14(4):933-40.

PMID:
16142354
27.

Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?

Clavio M, Balleari E, Garrone A, Ballerini F, Varaldo R, Michelis GL, Balocco M, Abdall N, Colombo N, Grasso R, Gobbi M.

J Exp Clin Cancer Res. 2005 Mar;24(1):5-16. Review.

PMID:
15943026
28.

Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.

Clavio M, Pierri I, Venturino C, Garrone A, Canepa L, Miglino M, Varaldo R, Ballerini F, Michelis GL, Balocco M, Abdall N, Gatto S, Gobbi M.

Leuk Lymphoma. 2004 Dec;45(12):2527-30. No abstract available.

PMID:
15621773
29.

Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.

Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M.

Ann Hematol. 2004 Nov;83(11):696-703. Epub 2004 Aug 18.

PMID:
15322763
30.

Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report.

Clavio M, Nobili F, Balleari E, Girtler N, Ballerini F, Vitali P, Rosati P, Venturino C, Varaldo R, Gobbi M, Ghio R, Rodriguez G.

Eur J Haematol. 2004 Feb;72(2):113-20.

PMID:
14962248
31.

Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.

Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.

J Exp Clin Cancer Res. 2002 Dec;21(4):481-7.

PMID:
12636093
32.

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.

Barosi G, Elliott M, Canepa L, Ballerini F, Piccaluga PP, Visani G, Marchetti M, Pozzato G, Zorat F, Tefferi A.

Leuk Lymphoma. 2002 Dec;43(12):2301-7. Erratum in: Leuk Lymphoma. 2009 Dec;50(12):2102. Giovanni, Barosi [corrected to Barosi, Giovanni]; Michelle, Elliott [corrected to Elliott, Michelle]; Letizia, Canepa [corrected to Canepa, Letizia]; Filippo, Ballerini [corrected to Ballerini, Filippo]; Pier Paolo, Piccaluga [corrected to Piccaluga, Pier.

PMID:
12613516
33.

Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.

Miglino M, Berisso G, Grasso R, Canepa L, Clavio M, Pierri I, Pietrasanta D, Gatto S, Varaldo R, Ballerini F, Verdiani S, Casarino L, DeStefano F, Sessarego M, Dominietto A, Raiola AM, Bregante S, di Grazia C, Gobbi M, Bacigalupo A.

Bone Marrow Transplant. 2002 Nov;30(9):579-85.

34.

Treatment of non-Hodgkin's lymphoma in the elderly. The Italian studies.

Salvagno L, Errante D, Bianco A, Palmisano V, Ballerini F, Boccalon M, Aversa S, Monfardini S.

Tumori. 2002 Jan-Feb;88(1 Suppl 1):S20-5. No abstract available.

PMID:
11989915
35.

Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.

Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, Musto P, Di Raimondo F, Ledda A, Lauria F, Masini L, Gobbi M, Vacca A, Ria R, Cangini D, Tura S, Baccarani M, Cavo M.

Haematologica. 2002 Apr;87(4):408-14.

36.

Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?

Clavio M, Quintino S, Venturino C, Ballerini F, Varaldo R, Gatto S, Galbusera V, Garrone A, Grasso R, Canepa L, Miglino M, Pierri I, Gobbi M.

J Exp Clin Cancer Res. 2001 Sep;20(3):351-8. Review.

PMID:
11718214
37.

Thalidomide in agnogenic and secondary myelofibrosis.

Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M, Miglino M, Pierri I, Gobbi M.

Br J Haematol. 2001 Nov;115(2):313-5.

PMID:
11703326
38.

Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.

Miglino M, Santini G, Grasso R, Pietrasanta D, Clavio M, Pierri I, Canepa L, Nati S, Ballerini F, Varaldo R, Palmisano G, Gobbi M.

Haematologica. 2001 Jul;86(7):706-14.

39.

Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells.

Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC, Sozzani S, Allavena P, Mantovani A, Ruco LP.

Am J Pathol. 2000 Mar;156(3):831-7.

40.

GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.

Pierri I, Clavio M, Beltrami G, Cavaliere M, Lanza L, Miglino M, Canepa L, Pietrasanta D, Ballerini F, Quintino S, Gatto S, Celesti L, Carrara P, Varese P, Gobbi M.

J Exp Clin Cancer Res. 1999 Mar;18(1):55-60.

PMID:
10374678
41.

First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.

Clavio M, Miglino M, Spriano M, Pietrasanta D, Vallebella E, Celesti L, Canepa L, Pierri I, Cavaliere M, Ballerini F, Beltrami G, Rossi E, Vimercati R, Bruni R, Congiu M, Nati S, Damasio E, Santini G, Gobbi M.

Eur J Haematol. 1998 Sep;61(3):197-203.

PMID:
9753416

Supplemental Content

Loading ...
Support Center